Trials / Terminated
TerminatedNCT00151476
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
A Registry-Based Observational Study Assessing Clinical Outcomes In Familial Adenomatous Polyposis In Patients Receiving Celecoxib (Celebrex(Registered), Onsenal(Registered)) Compared With Control Patients
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 68 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This is a registry-based observational study assessing clinical outcomes in FAP patients receiving celecoxib compared with historical/concurrent registry patients who have not received celecoxib. Both retrospective and prospective data will be utilized. No sampling methods apply.
Detailed description
The study prematurely discontinued on April 11, 2008 due to slow enrollment. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celecoxib | 800 mg total daily dosing |
| OTHER | Routine Medical Care |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2005-09-09
- Last updated
- 2024-09-04
- Results posted
- 2010-03-04
Locations
4 sites across 4 countries: United States, Canada, Denmark, Spain
Source: ClinicalTrials.gov record NCT00151476. Inclusion in this directory is not an endorsement.